Patents by Inventor Rafal Kaminski

Rafal Kaminski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240098181
    Abstract: A device, system and method for transferring calls to public-safety answering points is provided. A call routing devices receives, from a plurality of public-safety answering points (PSAPs), status data indicating respective states of the plurality of PSAPs. The call routing device receives a call to be routed to a first PSAP of the plurality of PSAPs. The call routing device generates a list of other PSAPs, of the plurality of PSAPs, prioritized according to the status data. The call routing device routes the call to the first PSAP, the call routed with the list. The call routing device receives, from the first PSAP, an indication to transfer the call to a second PSAP selected from the list. The call routing device transfers the call to the second PSAP.
    Type: Application
    Filed: September 20, 2022
    Publication date: March 21, 2024
    Inventor: Rafal KAMINSKI
  • Publication number: 20230390367
    Abstract: Compositions include gene editing agents, e.g. CRISPR that employ Cas13a for editing and inactivating sequences in the Coronavirus genome.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 7, 2023
    Inventors: Kamel Khalili, Rafal Kaminski, Shuren Liao
  • Patent number: 11824914
    Abstract: Techniques for streaming media to a public safety access point without incurring additional user costs are provided. A media stream from a mobile device is received at a communications network. The media stream being streamed from the mobile device to a social media platform in a first format. A request from a Public Safety Access Point to stream the media from the mobile device in a second format is received at the communications network. A request is sent to the mobile device to send the media stream in the second format. The media stream received from the mobile device in the second format is converted to the first format. The media stream received in the second format is sent to the Public Safety Access Point. The converted media stream in the first format is sent to the social media platform.
    Type: Grant
    Filed: November 15, 2022
    Date of Patent: November 21, 2023
    Assignee: MOTOROLA SOLUTIONS, INC.
    Inventors: Filip Norys, Grzegorz Gustof, Rafal Kaminski, Robert Orzechowski
  • Publication number: 20230220361
    Abstract: Migration of HIV-1 infected monocytes across the endothelial barrier plays an essential role in establishing and maintenance of viral reservoir in the brain and leads to neuroinflammation, neuronal damage, and subsequent HIV-induced central nervous system (CNS) dysfunction. These processes continue despite antiretroviral therapy (ART) due to limited pharmacological permeability of the blood-brain barrier, the presence of residual viral replication, and the reactivation of latent viruses. Compositions comprising Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonucleases targeted to activated leukocytes cell adhesion molecule (ALCAM/CD166), chemotactic recruitment (CCR2/5), adhesion to the endothelium (ALCAM) and junctional diapedesis (JAM-A) achieves maximum repression of leukocyte transmigration and block of the spread of the virus to different tissues and organs.
    Type: Application
    Filed: August 5, 2022
    Publication date: July 13, 2023
    Inventors: Rafal KAMINSKI, Tricia BURDO
  • Publication number: 20190367924
    Abstract: Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in a retrovirus and a receptor used by a retrovirus for infecting a cell. The CRISPR construct edits, for example, proviral HIV DNA, thereby eliminating the provirus from an infected cell and simultaneously edits a viral receptor, e.g. CCR5 preventing infection and reinfection of the host.
    Type: Application
    Filed: February 16, 2018
    Publication date: December 5, 2019
    Applicant: Temple University - of the Commonwealth System of Higher Education
    Inventors: Kamel Khalili, Rafal Kaminski, Thomas Malcolm
  • Publication number: 20190085326
    Abstract: A CRISPR-endonuclease gene editing composition includes a guide RNA (gRNA) for targeting a specific viral sequence for cleavage by the endonuclease which introduces breaks in the double stranded DNA identified by the gRNA. Placing the gene encoding Cas9 under the control of a minimal promoter of, for example, HIV spanning the 5?-LTR, results in the activation by the HIV-1 transactivator protein, Tat. Co-expression of both a multiplex of, for example, HIV-specific gRNAs and endonuclease, e.g. Cas9, in cells results in the modification and/or excision of the segment of viral DNA, leading to the eradication of the virus in vitro and in vivo.
    Type: Application
    Filed: December 3, 2018
    Publication date: March 21, 2019
    Inventors: Kamel Khalili, Wenhui Hu, Rafal Kaminski, Thomas Malcolm
  • Patent number: 10087211
    Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 2, 2018
    Assignees: RESEARCH TRIANGLE INSTITUTE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott P. Runyon, Michael Rogawski, Edgar Cook, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr
  • Publication number: 20180021307
    Abstract: The present invention relates and the combination of lacosamide and brivaracetam for the preparation of a fixed dose combination that is useful in the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.
    Type: Application
    Filed: February 19, 2016
    Publication date: January 25, 2018
    Inventors: Rafal Kaminski, Karine Leclercq, Frank Dressen
  • Publication number: 20170051008
    Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 23, 2017
    Applicants: RESEARCH TRIANGLE INSTITUTE, The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Scott P. RUNYON, Michael ROGAWSKI, Edgar COOK, John KEPLER, Herman NAVARRO, Rafal KAMINSKI, Matthew ORR
  • Patent number: 9518080
    Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: December 13, 2016
    Assignees: RESEARCH TRIANGLE INSTITUTE, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Scott P Runyon, Michael Rogawski, Edgar Cook, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr
  • Publication number: 20140094619
    Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.
    Type: Application
    Filed: August 23, 2013
    Publication date: April 3, 2014
    Applicants: US GOV BY THE SEC. OF DEPT. OF HEALTH & HUMAN SERV, RESEARCH TRIANGLE INSTITUTE
    Inventors: Scott P. RUNYON, Michael ROGAWSKI, Edgar COOK, John KEPLER, Hernan NAVARRO, Rafal KAMINSKI, Matthew ORR
  • Patent number: 8575375
    Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: November 5, 2013
    Assignees: Research Triangle Institute, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Scott P. Runyon, Michael A. Rogawski, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr, Kevin M. Cook
  • Publication number: 20110092473
    Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.
    Type: Application
    Filed: June 16, 2008
    Publication date: April 21, 2011
    Applicants: Research Triangle Institute, US GOV BY THE SEC. OF DEPT. OF HEALTH & HUMAN SERV.
    Inventors: Scott P. Runyon, Michael Rogawski, Edgar Cook, Kevin M. Cook, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr